Core Insights - Rippling, an HR software startup, raised $450 million in Series G funding, achieving a valuation of $16.8 billion, focusing on global revenue growth over immediate profitability [1][4][5] Funding and Valuation - The funding round included participation from notable investors such as Y Combinator, Elad Gil, Sands Capital, GIC, and Goldman Sachs Growth [2] - The new valuation of $16.8 billion marks an increase from the previous valuation of $13.5 billion in early 2024 [4] Employee Equity and IPO Plans - Rippling plans to repurchase up to $200 million of equity from current and former employees through a tender offer, which may become an annual event [2][3] - The CEO stated that the company does not have immediate plans for an IPO, emphasizing the need for profitability before considering going public [4][6] Business Performance and Strategy - Rippling has surpassed $100 million in annual recurring revenue and serves over 20,000 customers with a suite of more than 20 products [5] - The company is prioritizing growth over profitability, indicating a strategic choice to expand rapidly rather than slow down for immediate profit [6] Legal Challenges - Rippling is involved in ongoing legal disputes with competitor Deel, including allegations of corporate espionage, which have raised questions about competitive practices in the tech industry [7][8]

Core Insights - MP Materials is strategically moving downstream into high-value rare earth magnet manufacturing, with its Fort Worth, TX facility serving as the production hub and engineering headquarters [1] Group 1: Facility Development and Operations - Construction of the Independence Facility began in February 2022, marking the first fully integrated rare earth metal, alloy, and magnet manufacturing operation in the U.S. [2] - The facility converts NdPr oxide from Mountain Pass into permanent magnets and precursor products, with integrated capabilities for magnet recycling [2] - In 2024, the company commissioned electrowinning capabilities to produce NdPr metal and added strip casting capabilities in 2025 for NdFeB alloy flake production [3] Group 2: Revenue Generation and Financial Performance - The Magnetics segment began generating revenues in Q1 2025, with $5.2 million from sales to General Motors, contributing $493 million to segment adjusted EBITDA [4] - Quarterly revenues increased to $19.9 million in Q2, $21.9 million in Q3, and $19.9 million in Q4 of 2025 [4] - For the full year 2025, the Magnetics segment generated $66.9 million in revenues, accounting for approximately 30% of total company revenues, and delivered $26.4 million in adjusted EBITDA [5] Group 3: Strategic Partnerships and Future Plans - In July 2025, MP Materials entered a long-term supply agreement with Apple for magnet development and recycling capabilities [6] - The company is expanding the Independence Facility's annual capacity to 3,000 MTs and plans to construct the 10X Facility, expected to produce 7,000 MTs annually starting in 2028 [7] - These efforts will increase overall U.S. rare earth magnet production capacity to an estimated 10,000 MTs per year, enhancing supply-chain resilience [8] Group 4: Market Performance and Valuation - MP Materials' shares have increased by 125.8% over the past year, outperforming the industry's growth of 58.5% [9] - The Magnetics segment's revenues in 2025 were $66.9 million, representing about 30% of total sales, with long-term supply agreements secured with General Motors and Apple [10] - The Zacks Consensus Estimate for MP Materials' 2026 earnings is 19 cents per share, improving from a loss of 24 cents in 2025, with a projected estimate of $1.12 per share for 2027 [11]

Core Viewpoint - Cheniere Energy, Inc. is recognized as a leading investment opportunity in the infrastructure sector, despite a recent price target reduction by JPMorgan, which still indicates significant upside potential for the stock [1][2]. Financial Performance and Guidance - Cheniere Energy is the largest producer of liquefied natural gas (LNG) in the U.S. and the second-largest globally [2]. - JPMorgan has lowered its price target for Cheniere from $338 to $325, maintaining an 'Overweight' rating, which suggests over 25% upside potential from the current share price [2]. - The company is expected to perform well in its upcoming Q1 report, with analysts predicting it will exceed its FY 2026 guidance due to favorable spreads [3]. - For FY 2026, Cheniere targets a consolidated adjusted EBITDA of $6.75 billion to $7.25 billion, compared to $6.94 billion achieved in the previous year [4]. - The expected distributable cash flow for FY 2026 is projected to be between $4.35 billion and $4.85 billion, down from $5.3 billion in 2025, reflecting higher production but lower spot margins [4]. - Spot margins have recently surged due to supply disruptions related to the US-Iran war, which may positively impact the company's financial outlook [4]. Market Position and Comparisons - Cheniere Energy has been included in lists of the best infrastructure and natural gas stocks to buy, indicating strong market positioning [1][5]. - While LNG is recognized as a valuable investment, there are suggestions that certain AI stocks may offer greater upside potential with less risk [5].

Core Viewpoint - Geopolitical tensions have driven WTI crude oil prices above $114 per barrel, yet oil producers are not capturing the expected financial benefits due to hedging, debt burdens, and margin compression, resulting in muted earnings growth for the SPDR S&P Oil & Gas Exploration & Production ETF (XOP) which has only gained approximately 30% year-to-date despite the oil price surge [1][4]. Group 1: Performance of XOP - XOP has delivered only a ~30% gain year-to-date, significantly lower than the oil price increase, as hedging programs and debt repayments have absorbed potential earnings [1][4]. - The fund's equal-weight structure exposes it to smaller, more leveraged drillers, which can negatively impact overall performance when these companies struggle [2][5]. - XOP is best suited for short-duration tactical investments during oil shocks rather than as a core energy holding, due to ongoing capital expenditure requirements and OPEC's supply responses limiting real returns [3][12]. Group 2: Structural Constraints - XOP's equal-weight methodology leads to a drag on performance as smaller, more leveraged companies are weighted equally with larger operators, which can pull down the entire fund during downturns [14]. - Continuous capital expenditures are necessary for E&P companies to maintain production levels, with ConocoPhillips spending $12.6 billion in 2025 and Occidental Petroleum spending $6.4 billion, limiting free cash flow available for shareholders [14]. - OPEC's response to price spikes, including announced output increases, adds bearish pressure on oil prices, with current predictions indicating a low probability of WTI reaching $110 in the near term [14]. Group 3: Comparison with Refiners - XOP's exposure to refiners is minimal, with Marathon Petroleum representing only ~2.5% of the fund, while it has significantly outperformed XOP with a 38% gain year-to-date compared to XOP's 30% [9]. - Refining margins for Marathon Petroleum expanded from $12.9 to $18.7 per barrel, contributing to its strong performance, which XOP investors have largely missed out on [9]. - Integrated majors like Chevron have also faced challenges, with a 30% decline in net income despite record production, highlighting the difficulties faced by pure-play E&P companies that dominate XOP's holdings [10].

Sign in Sign in to access your portfolio ...

"This five-store agreement is a meaningful milestone as we expand deeper into Ontario and prepare for Atlantic Canada. "It reflects both the strength of the brand and the confidence franchisees have in our long-term vision. There's a clear path ahead, and I couldn't be more excited about the future, with site selection in Ontario already underway." The company links the new agreement to its franchise support framework, which it says covers recruitment, site selection guidance, operational training, marketin ...

Core Viewpoint - Bill Ackman has made significant investments in Amazon, Meta, and Fannie Mae, indicating strong confidence in the long-term value of these companies, particularly in AI infrastructure and digital advertising [1][3]. Group 1: Amazon - Ackman's position in Amazon has grown to 11.76% of his portfolio, driven by strong momentum in Amazon's cloud (AWS) and advertising businesses [5][8]. - AWS revenue reached $35.58 billion in Q4 2025, growing 24% year-over-year, marking its fastest growth in 13 quarters, while the advertising segment generated $21.32 billion, up 23% [6][8]. - Despite a 65.95% year-over-year decline in free cash flow to $11.19 billion, Ackman believes that Amazon's aggressive spending on AI and other initiatives will yield long-term benefits [7][8]. - Analysts remain bullish on Amazon, with 64 out of 68 rating the stock a Buy or Strong Buy, and a consensus price target of $281.27, while shares are currently trading around $238.98, up 31.54% over the past year [8]. Group 2: Meta Platforms - Ackman's investment in Meta represents 9.36% of his portfolio, initiated during Q1 2026, with a focus on the company's long-term AI potential and undervalued stock price [9][11]. - Meta reported $59.89 billion in revenue for Q4 2025, a 23.8% increase year-over-year, with ad impressions up 18% and average ad prices increasing by 6% [10][11]. - The company is expected to spend between $115 billion and $135 billion on capital expenditures in 2026, while Reality Labs reported a $19.2 billion operating loss in 2025 [10]. - Despite concerns over spending, Meta's operating cash flow increased by 26.8% to $115.8 billion, and analysts are optimistic, with 61 out of 67 rating the stock a Buy or Strong Buy, and a consensus price target of $855.68 compared to the current share price of approximately $628.55 [11]. Group 3: Fannie Mae - Fannie Mae is considered Ackman's highest-upside investment, with the hedge fund being the largest common shareholder, holding over 210 million shares [12][13]. - Ackman has maintained his position since November 2013, betting on the potential privatization of Fannie Mae and Freddie Mac, which he believes could lead to significant returns [12][13]. - Fannie Mae generated $14.36 billion in net income in 2025, with a net worth of approximately $109 billion, but faces a $193 billion capital shortfall under current regulations [13][14]. - The stock is currently priced at around $8.25 per share, offering substantial upside if Ackman's thesis on privatization materializes, although it remains a speculative investment dependent on government actions [14].

Core Viewpoint - The VanEck BDC Income ETF (BIZD) aims to provide income through a diversified portfolio of Business Development Companies (BDCs), but the current dividend safety across its top holdings is inconsistent, warranting careful evaluation before assuming the sustainability of its yield [1][6]. Group 1: Income Generation Mechanism - BDCs are specialized lenders that provide credit to middle-market companies unable to access public debt markets, and they are required by law to distribute at least 90% of taxable income to shareholders, resulting in high yields [2]. - BIZD collects dividends from over 25 individual BDCs, with Ares Capital being the largest holding at 13.1%, followed by Blue Owl Capital Corp at 7.9%, Main Street Capital at 6.7%, Golub Capital BDC at 2.9%, and FS KKR Capital at 2.7% [2]. Group 2: Impact of Federal Reserve Rates - The income generated by BDCs is primarily floating-rate, meaning that when the Federal Reserve cuts rates, portfolio yields decrease. The Fed has reduced rates three times since September 2025, lowering the federal funds rate from 4.5% to 3.75%, which poses a significant challenge for BIZD's holdings [3]. Group 3: Performance of Key Holdings - Ares Capital is the most critical position in BIZD, maintaining a core EPS of $0.50 per share throughout 2025, which comfortably covers its $0.48 quarterly dividend. Net investment income per share ranged from $0.48 to $0.54, although weighted average portfolio yields fell from 11.1% to 10.3% [4]. - Despite Ares Capital's stability, two major holdings in BIZD have already cut their dividends in 2026, indicating uneven dividend safety across the portfolio [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Aquestive Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on May 4, 2026 [1]. Group 1: Class Action Details - Investors who bought Aquestive securities between June 16, 2025, and January 8, 2026, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by visiting the provided link or contacting the firm directly [3][6]. - The lawsuit alleges that the defendants made false or misleading statements regarding the New Drug Application for Anaphylm and concealed significant human factors related to its sublingual film [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms issuing notices may lack the necessary experience [4]. - Rosen Law Firm has a strong history in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its performance in securities class action settlements, ranking highly in the industry since 2013 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Aldeyra Therapeutics, Inc. securities between November 3, 2023, and March 16, 2026, of the May 29, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Aldeyra securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by visiting the provided link or contacting the firm directly [3][6]. - The deadline to move the Court to serve as lead plaintiff is May 29, 2026, and a lead plaintiff acts on behalf of other class members [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4]. Group 3: Case Allegations - The lawsuit alleges that defendants made false and misleading statements regarding the clinical trials of reproxalap, an Aldeyra drug candidate, leading to unreliable positive findings [5]. - It is claimed that the inconsistency of trial results rendered the defendants' statements about Aldeyra's business and prospects materially false and misleading [5]. - The lawsuit asserts that when the true details were revealed, investors suffered damages as a result [5].